Finding answers to discover a cure for myeloma is one of our main objectives at Myeloma UK. We are committed to achieving this with the help of supporters such as Alison Goldberg and Sara Phillips, who are trustees of The Joyce and Norman Freed Charitable Trust, which they established in 2016 to help fund projects…
OPTIMISING CURRENT TREATMENTS The number of drugs available as myeloma treatment has grown significantly over the last two decades with discovery and approval of immunomodulatory drugs (thalidomide, lenalidomide (Revlimid®) and pomalidomide (Imnovid®)), proteasome inhibitors (bortezomib (Velcade®), cafilzomib (Kyprolis®) and ixazomib (Ninlaro®)), histone deacetylase inhibitors (panobinostat) and monoclonal antibody drugs (daratumumab (Darzalex®) and elotuzumab (Empliciti®)). However,…
Common Terminology Criteria for Adverse Events (CTCAE) is widely accepted as the standard classification and severity grading scale for adverse events in cancer therapy, clinical trials and other oncology settings. Version 5.0 is the most updated document (November 27, 2017)
The European Myeloma Network have published recommendations on diagnostic, prognostic and monitoring tests for patients with myeloma.
The European Myeloma Network have published recommendations on diagnostic, prognostic and monitoring tests for patients with myeloma.
These guidelines, produced by the National Institute for Health and Care Excellence (NICE), set out new recommendations for the diagnosis, treatment and care of myeloma patients with the aim of providing consistently excellent patient-focused care within the NHS in England. Update information October 2018: Recommendations 1.8.13 to 1.8.17 were replaced by NICE’s guideline on venous thromboembolism in…
These guidelines, produced by the National Institute for Health and Care Excellence (NICE), set out new recommendations for the diagnosis, treatment and care of myeloma patients with the aim of providing consistently excellent patient-focused care within the NHS in England. Update information October 2018: Recommendations 1.8.13 to 1.8.17 were replaced by NICE’s guideline on venous thromboembolism in…
